Genzyme, the division of French drug maker Sanofi Aventis with much of its operations in the MetroWest area, and its partner, California-based Isis Pharmaceuticals Inc., announced that they are applying to market a cholesterol-lowering drug in Europe.
The companies are seeking approval from the European Medicines Agency for the drug mipomersen to be used on patients with a genetic disease that results in high LDL-C levels. The disease puts patients at risk for premature heart disease.
The companies would market the drug under the name Kynamro. Isis developed the drug and licensed it to Genzyme.
